143 related articles for article (PubMed ID: 30908646)
1. Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy.
Yarian F; Alibakhshi A; Eyvazi S; Arezumand R; Ahangarzadeh S
J Cell Physiol; 2019 Aug; 234(10):16724-16738. PubMed ID: 30908646
[TBL] [Abstract][Full Text] [Related]
2. Cancer-targeting antibody-drug conjugates drive dealmaking frenzy.
Senior M
Nat Biotechnol; 2024 Mar; 42(3):362-366. PubMed ID: 38409588
[No Abstract] [Full Text] [Related]
3. Advances in targeted therapy for pancreatic cancer.
Xing L; Lv L; Ren J; Yu H; Zhao X; Kong X; Xiang H; Tao X; Dong D
Biomed Pharmacother; 2023 Dec; 168():115717. PubMed ID: 37862965
[TBL] [Abstract][Full Text] [Related]
4. Introduction of Carbonyl Groups into Antibodies.
Gulyak EL; Alferova VA; Korshun VA; Sapozhnikova KA
Molecules; 2023 Dec; 28(23):. PubMed ID: 38067618
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates in oncology: insights into Current challenges.
Al Meslamani AZ; Bostanudin MF
Expert Opin Biol Ther; 2023; 23(11):1035-1038. PubMed ID: 37883244
[No Abstract] [Full Text] [Related]
6. How antibody-drug conjugates aim to take down cancer.
Plackett B
Nature; 2024 May; 629(8014):S2-S3. PubMed ID: 38811702
[No Abstract] [Full Text] [Related]
7. Current status and contemporary approaches to the discovery of antitumor agents from higher plants.
Agarwal G; Carcache PJB; Addo EM; Kinghorn AD
Biotechnol Adv; 2020; 38():107337. PubMed ID: 30633954
[TBL] [Abstract][Full Text] [Related]
8. Patient, industry, and regulatory perspective on antibody-drug conjugates dose optimization.
Hamed S; Li C; Liao MZ; Warwick L; Zhou Z
Clin Transl Sci; 2024 Mar; 17(3):e13759. PubMed ID: 38501292
[No Abstract] [Full Text] [Related]
9. Use of Closed System Transfer Devices (CSTDs) with Protein-Based Therapeutic Drugs-A Non-Solution for a Non-Problem?
Fast J; Christian T; Crul M; Jiskoot W; Nejadnik MR; Medina A; Radwick A; Sreedhara A; Tole H
J Pharm Sci; 2024 Feb; 113(2):298-305. PubMed ID: 37984700
[No Abstract] [Full Text] [Related]
10. Bioanalytical Approaches to Support the Development of Antibody-Oligonucleotide Conjugate (AOC) Therapeutic Proteins.
Murphy A; Hill R; Berna M
Xenobiotica; 2024 Apr; ():1-23. PubMed ID: 38607350
[TBL] [Abstract][Full Text] [Related]
11. Generation and validation of structurally defined antibody-siRNA conjugates.
Nanna AR; Kel'in AV; Theile C; Pierson JM; Voo ZX; Garg A; Nair JK; Maier MA; Fitzgerald K; Rader C
Nucleic Acids Res; 2020 Jun; 48(10):5281-5293. PubMed ID: 32347936
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents.
Dovgan I; Koniev O; Kolodych S; Wagner A
Bioconjug Chem; 2019 Oct; 30(10):2483-2501. PubMed ID: 31339691
[TBL] [Abstract][Full Text] [Related]
13. A Genome-Wide Study of Single-Nucleotide Polymorphisms in MicroRNAs and Further In Silico Analysis Reveals Their Putative Role in Susceptibility to Late-Onset Alzheimer's Disease.
Herrera-Espejo S; Santos-Zorrozua B; Alvarez-Gonzalez P; Martin-Guerrero I; M de Pancorbo M; Garcia-Orad A; Lopez-Lopez E
Mol Neurobiol; 2021 Jan; 58(1):55-64. PubMed ID: 32892277
[TBL] [Abstract][Full Text] [Related]
14. miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease.
Readhead B; Haure-Mirande JV; Mastroeni D; Audrain M; Fanutza T; Kim SH; Blitzer RD; Gandy S; Dudley JT; Ehrlich ME
Acta Neuropathol; 2020 Sep; 140(3):295-315. PubMed ID: 32666270
[TBL] [Abstract][Full Text] [Related]
15.
Mueller C; Berry JD; McKenna-Yasek DM; Gernoux G; Owegi MA; Pothier LM; Douthwright CL; Gelevski D; Luppino SD; Blackwood M; Wightman NS; Oakley DH; Frosch MP; Flotte TR; Cudkowicz ME; Brown RH
N Engl J Med; 2020 Jul; 383(2):151-158. PubMed ID: 32640133
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer's disease pathogenesis.
Cao J; Huang M; Guo L; Zhu L; Hou J; Zhang L; Pero A; Ng S; El Gaamouch F; Elder G; Sano M; Goate A; Tcw J; Haroutunian V; Zhang B; Cai D
Mol Psychiatry; 2021 Sep; 26(9):4687-4701. PubMed ID: 32632205
[TBL] [Abstract][Full Text] [Related]
17. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.
Debacker AJ; Voutila J; Catley M; Blakey D; Habib N
Mol Ther; 2020 Aug; 28(8):1759-1771. PubMed ID: 32592692
[TBL] [Abstract][Full Text] [Related]
18. miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer's disease.
Rodriguez-Ortiz CJ; Prieto GA; Martini AC; Forner S; Trujillo-Estrada L; LaFerla FM; Baglietto-Vargas D; Cotman CW; Kitazawa M
Aging Cell; 2020 Mar; 19(3):e13118. PubMed ID: 32087004
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a G-Quadruplex Structure in Pre-miRNA-1229 and in Its Alzheimer's Disease-Associated Variant rs2291418: Implications for miRNA-1229 Maturation.
Imperatore JA; Then ML; McDougal KB; Mihailescu MR
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991575
[TBL] [Abstract][Full Text] [Related]
20. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease.
Kenny A; Jiménez-Mateos EM; Zea-Sevilla MA; Rábano A; Gili-Manzanaro P; Prehn JHM; Henshall DC; Ávila J; Engel T; Hernández F
Sci Rep; 2019 Oct; 9(1):15437. PubMed ID: 31659197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
